Concentration and Methylation of Cell-Free DNA from Blood Plasma As Diagnostic Markers of Renal Cancer

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2016 Oct 12

PMID 27725787

Citations 35

Authors

Inessa Skrypkina

Liudmyla Tsyba

Kateryna Onyshchenko

Dmytro Morderer

Olena Kashparova

Oleksii Nikolaienko

Grigory Panasenko

Sergii Vozianov

Alina Romanenko

Alla Rynditch

Affiliations

Soon will be listed here.

Abstract

The critical point for successful treatment of cancer is diagnosis at early stages of tumor development. Cancer cell-specific methylated DNA has been found in the blood of cancer patients, indicating that cell-free DNA (cfDNA) circulating in the blood is a convenient tumor-associated DNA marker. Therefore methylated cfDNA can be used as a minimally invasive diagnostic marker. We analysed the concentration of plasma cfDNA and methylation of six tumor suppressor genes in samples of 27 patients with renal cancer and 15 healthy donors as controls. The cfDNA concentrations in samples from cancer patients and healthy donors was measured using two different methods, the SYBR Green I fluorescence test and quantitative real-time PCR. Both methods revealed a statistically significant increase of cfDNA concentrations in cancer patients. Hypermethylation on cfDNA was detected for the (74.1%), (51.9%), (55.6%), and (62.9%) genes in patients with renal cancer. Promoter methylation of and genes was not found on cfDNA. Our results confirmed that the cfDNA level and methylation of CpG islands of , , and genes in blood plasma can be used as noninvasive diagnostic markers of cancer.

Citing Articles

Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma.

Omri L, Naigeon M, Flippot R, Gavira-Diaz J, Poveda-Ferriols J, Nguyen D Explor Target Antitumor Ther. 2024; 5(6):1199-1222.

PMID: 39465007 PMC: 11502076. DOI: 10.37349/etat.2024.00271.

Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications.

Gerke M, Jansen C, Bilen M Cancers (Basel). 2024; 16(12).

PMID: 38927984 PMC: 11201475. DOI: 10.3390/cancers16122280.

Clinical application of circulating cell-free lymphoma DNA for fast and precise diagnosis of Burkitt lymphoma: Precision medicine for sub-Saharan Africa.

Chamba C, Mbulaiteye S, Balandya E, Schuh A Camb Prism Precis Med. 2024; 1:e13.

PMID: 38550928 PMC: 10953760. DOI: 10.1017/pcm.2023.1.

Preoperative cell-free DNA concentration in plasma as a diagnostic and prognostic biomarker of clear cell renal cell carcinoma.

Milecki T, Kluzek K, Pstrag N, Antczak A, Cieslikowski W, Wichtowski M Contemp Oncol (Pozn). 2024; 27(4):284-291.

PMID: 38405214 PMC: 10883193. DOI: 10.5114/wo.2023.135366.

E74-like Factor 5 Promoter Methylation in Circulating Tumor DNA as a Potential Prognostic Marker in Breast Cancer Patients.

Salimi M, Rastegarpouyani S Asian Pac J Cancer Prev. 2023; 24(12):4035-4041.

PMID: 38156835 PMC: 10909102. DOI: 10.31557/APJCP.2023.24.12.4035.

References

Joo M, Kim K, Park J, Yoo H, Choe J, Kim H . CpG island promoter hypermethylation of Ras association domain family 1A gene contributes to gastric carcinogenesis. Mol Med Rep. 2014; 11(4):3039-46. DOI: 10.3892/mmr.2014.3055. View

Peters I, Rehmet K, Wilke N, Kuczyk M, Hennenlotter J, Eilers T . RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis. Mol Cancer. 2007; 6:49. PMC: 1939711. DOI: 10.1186/1476-4598-6-49. View

Zochbauer-Muller S, Fong K, Maitra A, Lam S, Geradts J, Ashfaq R . 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 2001; 61(9):3581-5. View

Ghosh A, Ghosh S, Maiti G, Sabbir M, Zabarovsky E, Roy A . Frequent alterations of the candidate genes hMLH1, ITGA9 and RBSP3 in early dysplastic lesions of head and neck: clinical and prognostic significance. Cancer Sci. 2010; 101(6):1511-20. PMC: 11159363. DOI: 10.1111/j.1349-7006.2010.01551.x. View

Feng G, Ye X, Fang F, Pu C, Huang H, Li G . Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma. Dis Markers. 2013; 34(2):105-11. PMC: 3810240. DOI: 10.3233/DMA-120950. View

Hadaczek P, Siprashvili Z, Markiewski M, Domagala W, Druck T, McCue P . Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res. 1998; 58(14):2946-51. View

Shi H, Li Y, Wang X, Lu C, Yang L, Gu C . Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis. PLoS One. 2013; 8(10):e76787. PMC: 3792894. DOI: 10.1371/journal.pone.0076787. View

Roth C, Pantel K, Muller V, Rack B, Kasimir-Bauer S, Janni W . Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer. 2011; 11:4. PMC: 3024991. DOI: 10.1186/1471-2407-11-4. View

Shenoy N, Vallumsetla N, Zou Y, Galeas J, Shrivastava M, Hu C . Role of DNA methylation in renal cell carcinoma. J Hematol Oncol. 2015; 8:88. PMC: 4511443. DOI: 10.1186/s13045-015-0180-y. View

10.

Levenson V . DNA methylation as a universal biomarker. Expert Rev Mol Diagn. 2010; 10(4):481-8. PMC: 2933138. DOI: 10.1586/erm.10.17. View

11.

Roy S, Bingle L, Marshall J, Bass R, Ellis V, Speight P . The role of α9β1 integrin in modulating epithelial cell behaviour. J Oral Pathol Med. 2011; 40(10):755-61. DOI: 10.1111/j.1600-0714.2011.01050.x. View

12.

Mambole A, Bigot S, Baruch D, Lesavre P, Halbwachs-Mecarelli L . Human neutrophil integrin alpha9beta1: up-regulation by cell activation and synergy with beta2 integrins during adhesion to endothelium under flow. J Leukoc Biol. 2010; 88(2):321-7. DOI: 10.1189/jlb.1009704. View

13.

Dworkin A, Huang T, Toland A . Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 2009; 19(3):165-71. PMC: 2734184. DOI: 10.1016/j.semcancer.2009.02.007. View

14.

Jung K, Fleischhacker M, Rabien A . Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. Clin Chim Acta. 2010; 411(21-22):1611-24. DOI: 10.1016/j.cca.2010.07.032. View

15.

Hoye A, Couchman J, Wewer U, Fukami K, Yoneda A . The newcomer in the integrin family: integrin α9 in biology and cancer. Adv Biol Regul. 2012; 52(2):326-39. DOI: 10.1016/j.jbior.2012.03.004. View

16.

Demokan S, Chuang A, Pattani K, Sidransky D, Koch W, Califano J . Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer. Oncol Rep. 2013; 31(2):1014-20. PMC: 3896520. DOI: 10.3892/or.2013.2927. View

17.

Wasserkort R, Kalmar A, Valcz G, Spisak S, Krispin M, Toth K . Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. BMC Cancer. 2013; 13:398. PMC: 3837632. DOI: 10.1186/1471-2407-13-398. View

18.

Lo K, Kwong J, Hui A, Chan S, To K, Chan A . High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 2001; 61(10):3877-81. View

19.

Pinzani P, Salvianti F, Zaccara S, Massi D, De Giorgi V, Pazzagli M . Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin Chim Acta. 2011; 412(23-24):2141-5. DOI: 10.1016/j.cca.2011.07.027. View

20.

Loginov V, Khodyrev D, Pronina I, Kazubskaia T, Ermilova V, Garkavtseva R . [Methylation of promoter region of RASSF1A gene and frequencies of allelic imbalances in chromosome 3 critical regions are correlated with progression of clear cell renal cell carcinoma]. Mol Biol (Mosk). 2009; 43(3):429-38. View